Affimed N.V.: Affimed Announces Proposed Public Offering of Common Shares

Heidelberg, Germany, November 7, 2019 -- Affimed N.V. ("Affimed" or the 
"Company") (Nasdaq: AFMD), a clinical stage biopharmaceutical company 
committed to giving patients back their innate ability to fight cancer, 
today announced that it has commenced an underwritten public offering of 
its common shares. The Company expects to grant the underwriters a 
30-day option to purchase up to an additional 15 percent of the number 
of common shares sold in connection with the offering. All of the shares 
in the offering will be sold by Affimed. This offering is subject to 
market conditions and there can be no assurance as to whether or when 
the offering may be completed, or as to the actual size or terms of the 
offering. 
 
   Jefferies LLC and SVB Leerink LLC are acting as joint book-running 
managers of the offering. A shelf registration statement relating to 
these securities filed with the Securities and Exchange Commission (the 
"SEC") was declared effective by the SEC on November 7, 2018. The 
offering will be made only by means of a prospectus and prospectus 
supplement. A preliminary prospectus supplement and accompanying 
prospectus related to the offering have been filed with the SEC and are 
available at the SEC's website located at www.sec.gov. Copies of the 
preliminary prospectus supplement and accompanying prospectus related to 
the offering may be obtained by contacting Jefferies LLC, Attention: 
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, 
New York, NY 10022, or by telephone at [phone] or by email at 
[e-mail], or SVB Leerink LLC, Attention: 
Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, 
by telephone at [phone], ext. 6132, or by email at 
[e-mail]. 
 
   This press release shall not constitute an offer to sell or a 
solicitation of an offer to buy, nor shall there be any sale of, these 
securities in any state or jurisdiction in which such offer, 
solicitation or sale would be unlawful prior to registration or 
qualification under the securities laws of any such state or 
jurisdiction. 
 
 
 
   About Affimed N.V. 
 
   Affimed (Nasdaq: AFMD) is a clinical stage biopharmaceutical company 
committed to giving patients back their innate ability to fight cancer. 
Affimed's fit-for-purpose ROCK(R) platform allows innate cell engagers 
to be designed for specific patient populations. The Company is 
developing single and combination therapies to treat hematologic and 
solid tumors. 
 
   Forward-looking Statements 
 
   This press release contains forward-looking statements. All statements 
other than statements of historical fact are forward-looking statements, 
which are often indicated by terms such as "anticipate," "believe," 
"could," "estimate," "expect," "goal," "intend," "look forward to," "may, 
" "plan," "potential," "predict," "project," "should," "will," "would" 
and similar expressions. Forward-looking statements appear in a number 
of places throughout this release and include statements regarding our 
intentions, beliefs, projections, outlook, analyses and current 
expectations concerning, among other things, the value of our ROCK(R) 
platform, our ongoing and planned preclinical development and clinical 
trials, our collaborations and development of our products in 
combination with other therapies, the timing of and our ability to make 
regulatory filings and obtain and maintain regulatory approvals for our 
product candidates our intellectual property position, our collaboration 
activities, our ability to develop commercial functions, expectations 
regarding clinical trial data, our results of operations, cash needs, 
financial condition, liquidity, prospects, future transactions, growth 
and strategies, the industry in which we operate, the trends that may 
affect the industry or us and the risks uncertainties and other factors 
described under the heading "Risk Factors" in Affimed's filings with the 
SEC. Given these risks, uncertainties and other factors, you should not 
place undue reliance on these forward-looking statements, and we assume 
no obligation to update these forward-looking statements, even if new 
information becomes available in the future. 
 
   Affimed Investor and Media Contact 
 
   Gregory Gin, Head of Investor Relations 
 
   E-Mail: [e-mail] 
 
 
 
 

(END) Dow Jones Newswires

November 07, 2019 16:11 ET (21:11 GMT)